Organisation paid for research Program year 2025 Source: CMS Open Payments

Florida Eye Associates Inc

Neither a doctor nor a teaching hospital

Research payments

$3,409,709

506 payments

Through program year 2025, Florida Eye Associates Inc is reported as receiving $3,409,709 in research payments, across 506 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$243,878	220
2024	Research	$590,609	130
2023	Research	$815,028	61
2022	Research	$1,071,153	56
2021	Research	$499,840	24
2020	Research	$50,194	6
2019	Research	$139,006	9

Breakdown

Who paid Research payments · program years 2019–2025

Bayer HealthCare Pharmaceuticals Inc. $996,386 192 payments
Genentech, Inc. $874,849 75 payments
EyePoint Pharmaceuticals US, Inc. $772,766 7 payments
Regeneron Pharmaceuticals, Inc. $666,576 205 payments
Kyowa Kirin, Inc. $54,251 20 payments
Astellas Pharma Global Development $44,881 7 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD $470,824 3 payments
BAY865321, HD 8mg, AMD - Ph 3 $428,167 27 payments
A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $424,526 187 payments
A phase 1, Multicenter, Prospective, Open-Label, Dose escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in subjects with Wet AMD $243,787 2 payments
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration $196,080 55 payments
Faricimab Dme Long Term Extension Rhone X $193,110 6 payments
Open Label Extension Study to Evaluate the Long Term Safety of Faricimab in Patients With Namd $180,497 5 payments
BAY 865321, Aflibercept 8mg in RVO $159,185 54 payments
A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy $139,006 9 payments
PH 2 Open Label Extension of Ahtra1 in Ga $129,821 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.